Experts in industry, research and pharma will discuss complex drug market and regulation

Leaders in biosimilar innovation will provide an in-depth, comparative analysis of the current global debates and trends in biosimilar regulation at the DIA 2014 50th Annual Meeting, from June 15 to 19 at the San Diego Convention Center. The “Trends in Biosimilars Regulation Within Developed and Emerging Markets” session will be held on June 19 at 10:45 a.m.

“Today’s experts in biosimilars will discuss key areas of the regulatory landscape for these complex drugs, highlight areas of agreement and disagreement, and explore trends across the world—in both emerging and developed markets,” said Barbara L. Kunz, DIA global chief executive.

As domestic and international regulators have pushed to create guidance for this new drug market, U.S. pharmaceutical manufacturers, legislators and those working in the drug development arena continue to debate how to regulate biosimilars.
 

Chaired by Dr. Andrew Robertson, director of global regulatory policy at Merck & Co., Inc., the session will feature a presentation by Dr. Sonica Sachdeva Batra, director of clinical development at Dr. Reddy’s Laboratories, on regional trends in biosimilar regulation in the Asia Pacific region. Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines, will give a presentation on the naming standards for biosimilar medicine.  

 

Contact: Tiffany Cohen
+1.202.499.4411
tcohen@reingold.com

 

 

###